All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Replicate Bio and Novo Nordisk collaborate on srRNA therapies
The research collaboration combines Replicate’s srRNA technology with Novo Nordisk’s expertise in drug development.
Teva launches generic version of Saxenda for weight management
Saxenda, used in combination with a calorie-restricted diet and physical activity, becomes the first generic GLP-1 receptor agonist available for weight loss in the US.
ExCellThera secures EC approval for Zemcelpro to treat blood cancer
Developed by Cordex Biologics, a subsidiary of ExCellThera, Zemcelpro is a personalised stem cell therapy product derived from a single cord blood unit.
US FDA approves updated Pfizer-BioNTech, Novavax Covid-19 vaccines
Pfizer and BioNTech’s updated Covid-19 vaccine, customised for the LP.8.1 sublineage, is approved for individuals aged 65 years and above.
BioArctic, Novartis collaborate on neurodegeneration treatment
The collaboration will focus on a potential treatment that combines BioArctic’s BrainTransporter technology with a neurodegeneration target.
AbbVie to acquire Gilgamesh’s MDD therapy for up to $1.2bn
Gilgamesh will create a new entity, dubbed Gilgamesh Pharma, to continue developing other projects, including its NMDA receptor antagonist blixeprodil.
BIO-Thera, STADA expand biosimilars partnership to include tocilizumab
Bio-Thera will develop, produce, and supply the tocilizumab biosimilar, while STADA will manage its marketing in the EU, UK, Switzerland, and other regions.
J&J to invest $2bn in North Carolina manufacturing expansion
The initiative involves the addition of a 160,000ft2 manufacturing facility at FUJIFILM’s Holly Springs site, creating 120 jobs.
Boehringer Ingelheim, AnGes collaborate on PAD gene therapy
Boehringer Ingelheim BioXcellence, the biopharmaceutical manufacturing unit of the German firm, will produce and supply API for AnGes’ hepatocyte growth factor (HGF) gene therapy.
Madrigal secures EC approval for Rezdiffra to treat MASH
Rezdiffra is an oral THR-β agonist intended for the treatment of adults having noncirrhotic MASH and moderate to advanced liver fibrosis.